NO20060108L - Look-through mutagenesis - Google Patents

Look-through mutagenesis

Info

Publication number
NO20060108L
NO20060108L NO20060108A NO20060108A NO20060108L NO 20060108 L NO20060108 L NO 20060108L NO 20060108 A NO20060108 A NO 20060108A NO 20060108 A NO20060108 A NO 20060108A NO 20060108 L NO20060108 L NO 20060108L
Authority
NO
Norway
Prior art keywords
polypeptide
libraries
mutagenesis
amino acids
function
Prior art date
Application number
NO20060108A
Other languages
English (en)
Norwegian (no)
Inventor
Roberto Crea
Original Assignee
Bioren Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren Inc filed Critical Bioren Inc
Publication of NO20060108L publication Critical patent/NO20060108L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20060108A 2003-06-27 2006-01-06 Look-through mutagenesis NO20060108L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48328203P 2003-06-27 2003-06-27
PCT/US2004/020306 WO2005003345A2 (en) 2003-06-27 2004-06-25 Look-through mutagenesis

Publications (1)

Publication Number Publication Date
NO20060108L true NO20060108L (no) 2006-03-24

Family

ID=33563915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060108A NO20060108L (no) 2003-06-27 2006-01-06 Look-through mutagenesis

Country Status (14)

Country Link
US (1) US20050136428A1 (enExample)
EP (1) EP1660655B1 (enExample)
JP (2) JP4791960B2 (enExample)
KR (1) KR20060034650A (enExample)
CN (1) CN1836041A (enExample)
AU (1) AU2004254352A1 (enExample)
BR (1) BRPI0412007A (enExample)
CA (1) CA2542192C (enExample)
ES (1) ES2609102T3 (enExample)
IL (1) IL172736A0 (enExample)
NO (1) NO20060108L (enExample)
RU (1) RU2005140664A (enExample)
WO (1) WO2005003345A2 (enExample)
ZA (1) ZA200510460B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
WO2006014498A2 (en) 2004-07-06 2006-02-09 Bioren, Inc. Universal antibody libraries
BRPI0511448A (pt) * 2004-07-06 2007-12-26 Bioren Inc anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
US9012369B2 (en) 2004-07-06 2015-04-21 Pfizer Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
WO2006094234A1 (en) * 2005-03-03 2006-09-08 Xencor, Inc. Methods for the design of libraries of protein variants
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
EP1877441A2 (en) * 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
ES2402576T3 (es) * 2005-11-14 2013-05-06 Bioren, Inc. Ultrahumanización de anticuerpos por generación y selección de bibliotecas cohorte y blast de cdr maduras previstas
US20110129414A1 (en) * 2005-11-15 2011-06-02 Balyasnikova Irina V Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof
JP2009519983A (ja) 2005-12-20 2009-05-21 アラーナ・テラピューティクス・リミテッド 部分的な新世界ザル結合領域を有するキメラ抗体
EA017417B1 (ru) 2006-02-01 2012-12-28 Сефалон Астралия Пти Лтд. КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007112054A2 (en) * 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2007136840A2 (en) * 2006-05-20 2007-11-29 Codon Devices, Inc. Nucleic acid library design and assembly
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US8131480B2 (en) 2006-10-02 2012-03-06 Sea Lane Biotechnologies Llc Construction of diverse synthetic peptide and polypeptide libraries
US20080287320A1 (en) * 2006-10-04 2008-11-20 Codon Devices Libraries and their design and assembly
JP5594895B2 (ja) * 2007-06-06 2014-09-24 ダニスコ・ユーエス・インク、ジェネンコー・ディビジョン タンパク質の能力の改良方法
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
EP2698380A1 (en) 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
EP2131245A3 (en) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithographic apparatus and its focus determination method
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
CN102625848A (zh) * 2009-07-17 2012-08-01 生物蛋白有限公司 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
US9753040B2 (en) 2010-12-01 2017-09-05 Mitsubishi Tanabe Pharma Corporation Polynucleotide construct capable of displaying fab in a cell-free translation system, and method for manufacturing and screening fab using same
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
WO2013158217A1 (en) * 2012-04-20 2013-10-24 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
DK2855674T4 (da) 2012-05-25 2022-11-21 Chr Hansen As Chymosinvarianter med forbedrede mælkekoagulerende egenskaber
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
KR101600899B1 (ko) * 2012-12-11 2016-03-09 주식회사 셀레믹스 초병렬적 핵산 합성법을 통한 dna 라이브러리의 동시 합성 방법
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
WO2015065987A1 (en) * 2013-11-01 2015-05-07 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CN104805507B (zh) * 2014-01-29 2019-01-22 杭州康万达医药科技有限公司 噬菌体展示文库及其应用和制备方法
BR112016017502B1 (pt) 2014-02-26 2023-10-24 Chr. Hansen A/S Variantes de polipeptídeo de quimosina isoladas método para a produção das mesmas e método para a fabricação de um produto de alimentação humana ou animal
US10118967B2 (en) 2014-10-21 2018-11-06 Ablynx N.V. Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies
CN107849550B (zh) 2015-06-22 2021-09-03 科.汉森有限公司 具有改善的性质的凝乳酶变体
JP2018525996A (ja) 2015-08-31 2018-09-13 セーホーエル．ハンセン アクティーゼルスカブ 改良された特性を有するキモシンの変異体
WO2017119499A1 (en) * 2016-01-08 2017-07-13 Momotaro-Gene Inc. A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
CN109640677A (zh) 2016-05-19 2019-04-16 科·汉森有限公司 具有改善的凝乳特性的凝乳酶的变体
JP7395251B2 (ja) 2016-05-19 2023-12-11 セーホーエル．ハンセン アクティーゼルスカブ 改善された凝乳特性を有するキモシン変異体
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
MX2020006297A (es) 2017-12-15 2020-12-07 Aleta Biotherapeutics Inc Variantes de cd19.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527809B1 (en) * 1990-04-05 1995-08-16 CREA, Roberto Walk-through mutagenesis
WO1995023813A1 (en) * 1994-03-04 1995-09-08 Merck & Co., Inc. In vitro antibody affinity maturation using alanine scanning mutagenesis
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning

Also Published As

Publication number Publication date
JP4791960B2 (ja) 2011-10-12
JP5358604B2 (ja) 2013-12-04
IL172736A0 (en) 2006-04-10
BRPI0412007A (pt) 2006-08-15
EP1660655B1 (en) 2016-11-02
EP1660655A2 (en) 2006-05-31
CN1836041A (zh) 2006-09-20
KR20060034650A (ko) 2006-04-24
CA2542192C (en) 2013-05-28
JP2007524390A (ja) 2007-08-30
AU2004254352A1 (en) 2005-01-13
ZA200510460B (en) 2006-11-29
WO2005003345A3 (en) 2005-03-24
RU2005140664A (ru) 2007-08-27
WO2005003345A2 (en) 2005-01-13
JP2011182794A (ja) 2011-09-22
ES2609102T3 (es) 2017-04-18
US20050136428A1 (en) 2005-06-23
CA2542192A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
NO20060108L (no) Look-through mutagenesis
BRPI0513155A (pt) mutagênese por inserção para desenvolver polipeptìdeos alterados com propriedades realçadas
Lomonte et al. Strategies in ‘snake venomics’ aiming at an integrative view of compositional, functional, and immunological characteristics of venoms
Venne et al. An improved workflow for quantitative N‐terminal charge‐based fractional diagonal chromatography (ChaFRADIC) to study proteolytic events in Arabidopsis thaliana
Seo et al. Strategy for comprehensive identification of post-translational modifications in cellular proteins, including low abundant modifications: application to glyceraldehyde-3-phosphate dehydrogenase
Lebedev et al. Discrimination of leucine and isoleucine in peptides sequencing with Orbitrap Fusion mass spectrometer
Tsiatsiani et al. Aspergillus niger prolyl endoprotease for hydrogen–deuterium exchange mass spectrometry and protein structural studies
Panjaitan et al. In silico analysis of bioactive peptides released from giant grouper (Epinephelus lanceolatus) roe proteins identified by proteomics approach
Luxmi et al. Cilia-based peptidergic signaling
Jorge et al. High‐sensitivity analysis of specific peptides in complex samples by selected MS/MS ion monitoring and linear ion trap mass spectrometry: application to biological studies
Wiezel et al. In-depth venome of the Brazilian rattlesnake Crotalus durissus terrificus: an integrative approach combining its venom gland transcriptome and venom proteome
WO2014150983A3 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (pcsk9)
Clark et al. Simple approach to assign disulfide connectivity using extracted ion chromatograms of electron transfer dissociation spectra
Rogniaux et al. Allergen relative abundance in several wheat varieties as revealed via a targeted quantitative approach using MS
BR112013017363A2 (pt) biblioteca de alphabody de cadeia única, mistura de bibliotecas de alphabody, ácido nucleico ou biblioteca de vetor, biblioteca de células hospedeiras, uso de uma biblioteca de alphabody de cadeia única, método para a produção de uma biblioteca de alphabody de cadeia única, método para a produção de um ou mais polipeptídeos de alphabody de cadeia única, polipeptíceo de alphabody de cadeia única, ácido nucleico, vetor e célula hospedeira
Huesgen et al. Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease
Babenko et al. Novel bradykinin-potentiating peptides and three-finger toxins from viper venom: Combined NGS venom gland transcriptomics and quantitative venom proteomics of the Azemiops feae viper
Freitas et al. New constitutive latex osmotin-like proteins lacking antifungal activity
WO2005116660A3 (en) Methods for making and using mass tag standards for quantitative proteomics
De Angelis et al. Effects of the varietal diversity and the thermal treatment on the protein profile of peanuts and hazelnuts
Hu et al. Multiplexed protein quantification in maize leaves by liquid chromatography coupled with tandem mass spectrometry: an alternative tool to immunoassays for target protein analysis in genetically engineered crops
De Canio et al. Novel IgE recognized components of Lolium perenne pollen extract: comparative proteomics evaluation of allergic patients sensitization profiles
Johnson et al. Aspartic acid isomerization characterized by high definition mass spectrometry significantly alters the bioactivity of a novel toxin from poecilotheria
Kumar et al. Proteomic profiling of secreted proteins from CHO cells using surface‐enhanced laser desorption ionization time‐of‐flight mass spectrometry
WO2003073351A3 (en) Screening process

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application